Approaching the Non-Responsive Psychotic Client

Immediate Decision-Making Framework

The American Psychiatric Association recommends initiating antipsychotic treatment based on collateral information about the patient's preferences and prior medication responses, while simultaneously assessing for safety concerns that would necessitate earlier intervention 1, 2
If the patient cannot engage in discussion due to psychosis, obtain input from friends and family immediately to inform treatment selection, including previous antipsychotic responses and side effects, known medication preferences or advance directives, baseline functioning and symptom severity, and substance use history 1, 2, 3, 4

Select an antipsychotic based on side-effect profile that would be least burdensome, using family input about patient values, and consider factors such as previous medication tolerability, concerns about sedation vs. activation, and metabolic risk factors 1, 2, 3
Engage the patient in decision-making as soon as it becomes appropriate as their mental state improves 1, 2, 3

Start with therapeutic doses rather than subtherapeutic doses to avoid treatment delays, and for first-episode psychosis, appropriate initial target doses are risperidone 2 mg/day or olanzapine 7.5-10 mg/day 1, 2, 5, 6, 7
Avoid large initial doses as they increase side effects without hastening recovery 5, 6, 7

Assess treatment effectiveness after 4 weeks at a therapeutic dose, and monitor for medication adherence, which is the most common cause of apparent treatment failure 1, 2, 8, 9
If significant positive symptoms persist after 4 weeks, switch to an alternative antipsychotic with a different pharmacodynamic profile 1, 2, 3

Do not delay treatment waiting for the patient to become cooperative if safety concerns exist, and avoid assuming non-response is treatment resistance before confirming adequate dose, duration, and adherence 1, 2, 8, 9